167 related articles for article (PubMed ID: 19556322)
21. HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer.
Abdel-Fatah TM; McArdle SE; Johnson C; Moseley PM; Ball GR; Pockley AG; Ellis IO; Rees RC; Chan SY
Br J Cancer; 2014 May; 110(10):2450-61. PubMed ID: 24755885
[TBL] [Abstract][Full Text] [Related]
22. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial.
Gluz O; Nitz UA; Harbeck N; Ting E; Kates R; Herr A; Lindemann W; Jackisch C; Berdel WE; Kirchner H; Metzner B; Werner F; Schütt G; Frick M; Poremba C; Diallo-Danebrock R; Mohrmann S;
Ann Oncol; 2008 May; 19(5):861-70. PubMed ID: 18174609
[TBL] [Abstract][Full Text] [Related]
23. E2F1 expression is related with the poor survival of lymph node-positive breast cancer patients treated with fluorouracil, doxorubicin and cyclophosphamide.
Han S; Park K; Bae BN; Kim KH; Kim HJ; Kim YD; Kim HY
Breast Cancer Res Treat; 2003 Nov; 82(1):11-6. PubMed ID: 14672398
[TBL] [Abstract][Full Text] [Related]
24. Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer.
Asano Y; Kashiwagi S; Onoda N; Noda S; Kawajiri H; Takashima T; Ohsawa M; Kitagawa S; Hirakawa K
Ann Surg Oncol; 2016 Apr; 23(4):1104-10. PubMed ID: 26511266
[TBL] [Abstract][Full Text] [Related]
25. Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy.
Mehta RR; McDermott JH; Hieken TJ; Marler KC; Patel MK; Wild LD; Das Gupta TK
J Clin Oncol; 1998 Jul; 16(7):2409-16. PubMed ID: 9667258
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Value of Tumor-Infiltrating Lymphocyte Density Assessed Using a Standardized Method Based on Molecular Subtypes and Adjuvant Chemotherapy in Invasive Breast Cancer.
Jang N; Kwon HJ; Park MH; Kang SH; Bae YK
Ann Surg Oncol; 2018 Apr; 25(4):937-946. PubMed ID: 29330719
[TBL] [Abstract][Full Text] [Related]
27. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.
Smith JW; Buyse ME; Rastogi P; Geyer CE; Jacobs SA; Patocskai EJ; Robidoux A; Conlin AK; Ansari B; Keogh GP; Stella PJ; Gross HM; Lord RS; Polikoff JA; Mauquoi C; Mamounas EP; Swain SM; Wolmark N
Clin Breast Cancer; 2017 Feb; 17(1):48-54.e3. PubMed ID: 27693116
[TBL] [Abstract][Full Text] [Related]
28. High-Risk Premenopausal Luminal A Breast Cancer Patients Derive no Benefit from Adjuvant Cyclophosphamide-based Chemotherapy: Results from the DBCG77B Clinical Trial.
Nielsen TO; Jensen MB; Burugu S; Gao D; Jørgensen CL; Balslev E; Ejlertsen B
Clin Cancer Res; 2017 Feb; 23(4):946-953. PubMed ID: 27601592
[No Abstract] [Full Text] [Related]
29. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of epithelial growth factor receptor (EGFR) predicts better response to neo-adjuvant chemotherapy in patients with triple-negative breast cancer.
Tang Y; Zhu L; Li Y; Ji J; Li J; Yuan F; Wang D; Chen W; Huang O; Chen X; Wu J; Shen K; Loo WT; Chow LW
J Transl Med; 2012 Sep; 10 Suppl 1(Suppl 1):S4. PubMed ID: 23046633
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study.
Jin X; Jiang YZ; Chen S; Yu KD; Shao ZM; Di GH
Oncotarget; 2015 Apr; 6(11):9600-11. PubMed ID: 25826079
[TBL] [Abstract][Full Text] [Related]
32. EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer.
Nogi H; Kobayashi T; Suzuki M; Tabei I; Kawase K; Toriumi Y; Fukushima H; Uchida K
Oncol Rep; 2009 Feb; 21(2):413-7. PubMed ID: 19148516
[TBL] [Abstract][Full Text] [Related]
33. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
34. [Correlation of metastasis-free survival in patients with breast cancer and changes in the direction of expression of multidrug resistance genes during neoadjuvant chemotherapy].
Litviakov NV; Garbukov EIu; Slonimskaia EM; Tsyganov MM; Denisov EV; Vtorushin SV; Khristenko KIu; Zav'ialova MV; Cherdyntseva NV
Vopr Onkol; 2013; 59(3):334-40. PubMed ID: 23909034
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
Malamou-Mitsi V; Gogas H; Dafni U; Bourli A; Fillipidis T; Sotiropoulou M; Vlachodimitropoulos D; Papadopoulos S; Tzaida O; Kafiri G; Kyriakou V; Markaki S; Papaspyrou I; Karagianni E; Pavlakis K; Toliou T; Scopa C; Papakostas P; Bafaloukos D; Christodoulou C; Fountzilas G
Ann Oncol; 2006 Oct; 17(10):1504-11. PubMed ID: 16968874
[TBL] [Abstract][Full Text] [Related]
36. [Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial].
Yuan P; Xu BH; Wang JY; Ma F; Li Q; Zhang P; Fan Y; Li Q; Wang WM
Zhonghua Zhong Liu Za Zhi; 2012 Jun; 34(6):465-8. PubMed ID: 22967451
[TBL] [Abstract][Full Text] [Related]
37. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group.
Colleoni M; Bonetti M; Coates AS; Castiglione-Gertsch M; Gelber RD; Price K; Rudenstam CM; Lindtner J; Collins J; Thürlimann B; Holmberg S; Veronesi A; Marini G; Goldhirsch A
J Clin Oncol; 2000 Feb; 18(3):584-90. PubMed ID: 10653873
[TBL] [Abstract][Full Text] [Related]
38. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF.
Poikonen P; Saarto T; Lundin J; Joensuu H; Blomqvist C
Br J Cancer; 1999 Aug; 80(11):1763-6. PubMed ID: 10468293
[TBL] [Abstract][Full Text] [Related]
39. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
[TBL] [Abstract][Full Text] [Related]
40. Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients.
Fehm T; Maimonis P; Weitz S; Teramoto Y; Katalinic A; Jäger W
Breast Cancer Res Treat; 1997 Mar; 43(1):87-95. PubMed ID: 9065602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
